May 15, 2023 / 04:00PM GMT
Reni Benjamin - JMP Securities LLC - Managing Director
So welcome, everyone. Welcome, good afternoon to the JMP Healthcare Conference. It's my pleasure to introduce Prelude Therapeutics, clinical-stage company developing targeted small molecules. Here to present for the company is founder and CEO, Kris Vaddi.
Kris, welcome to the conference, and thank you for joining us. I never know exactly who's in the audience and who might be listening to the webcast, whether they know the company. So if you could, in maybe three to five minutes, can you give us an overview of Prelude before we jump into some questions?
Kris Vaddi - Prelude Therapeutics Inc. - CEO
Glad to. And thank you very much for the opportunity to participate in this exciting conference. So as you said, Prelude is a small molecule oncology company. We founded the company in late 2016, really, with the idea of building a strong portfolio of highly differentiated and selective and potent small molecule agents to go after key mechanisms that are driving cancers in patients with highly unmet needs.
Prelude Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot